Basit öğe kaydını göster

dc.contributor.authorGiobbie-Hurder, Anita
dc.contributor.authorGelber, Richard D.
dc.contributor.authorPrice, Karen N.
dc.date.accessioned2022-02-18T10:57:41Z
dc.date.available2022-02-18T10:57:41Z
dc.date.issued2009
dc.identifier.citationGiobbie-Hurder A., Price K. N. , Gelber R. D. , "Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer", CLINICAL TRIALS, cilt.6, sa.3, ss.272-287, 2009
dc.identifier.issn1740-7745
dc.identifier.otherav_cb45894f-c696-496a-8fe0-afab320a70fc
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/180245
dc.identifier.urihttps://doi.org/10.1177/1740774509105380
dc.description.abstractBackground Aromatase inhibitors provide superior disease control when compared with tamoxifen as adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer.
dc.language.isoeng
dc.subjectResearch and Theory
dc.subjectHealth Sciences
dc.subjectDahili Tıp Bilimleri
dc.subjectReviews and References (medical)
dc.subjectTıbbi Ekoloji ve Hidroklimatoloji
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, ARAŞTIRMA VE DENEYSEL
dc.titleDesign, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer
dc.typeMakale
dc.relation.journalCLINICAL TRIALS
dc.contributor.departmentHarvard University , ,
dc.identifier.volume6
dc.identifier.issue3
dc.identifier.startpage272
dc.identifier.endpage287
dc.contributor.firstauthorID3376806


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster